


Consider **STRATICYTE™** and revolutionize the management of your oral precancer (OPMD) patients.



WHAT'S YOUR PATIENT'S ORAL CANCER RISK SCORE?



The **STRATICYTE** Test is available to order **NOW** in the US and Canada.

Order the test, **Proteocyte** does the rest.

STRATICYTE™
 Predict Oral Cancer Risk

Supported by:



MANAGING OPMD PATIENTS CAN BE A CHALLENGE.

Your patient has unfortunately been diagnosed with OPMD (Oral Potentially Malignant Disorder) and perhaps Dysplasia. Dysplasia grading is highly subjective with poor reproducibility and has limited prognostic value offering very confusing guidance.

In a large retrospective study by Chaturvedi et al, of the leukoplakia patients that progressed to cancer 39.6% had no Dysplasia whatsoever.¹

PROTEOCYTE AI can help with OPMD management by performing the prognostic STRATICYTE test using your patient's original biopsied tissue.

The **STRATICYTE** test can be considered for all clinically significant **red and white patches** affecting oral mucosa.

Managing the elevated-risk patient.

Using AI-driven digital histopathology, S100A7 (a cancer promoting protein) along with cellular features from **your patient's original biopsy sample** are quantitatively measured.



Your patient's test results are compared with a large cohort of similar cases with many years of follow up. An **accurate, objective and individualized 5-year cancer risk score** is generated to support management of your OPMD patient.

(STRATICYTE test sensitivity 96% / NPV 96%)²

“Early detection is the key to saving lives and improving outcomes related to oral cancer. Straticyte is an innovative new test that can help us to better risk stratify patients and personalize their treatment.”

Dr. Deepak Kademani, DMD, MD, FACS
Fellowship Director, Head and Neck
Oncologic and Reconstructive Surgery,
Minnesota Oral and Facial Surgery.

“Due to the uncertain progression of precancerous lesions, Straticyte provides a quantified tool for predicting the transformation of a lesion to a life-threatening cancer.

All in all, Straticyte has been an invaluable tool in providing my patients with the best care possible. I am confident that Straticyte will be a powerful tool in the management of precancerous leukoplakia.”

Dr James C. Melville, DDS FACS
Associate Professor
Department of Oral & Maxillofacial Surgery
Oral, Head & Neck Oncology and Microvascular
Reconstructive Surgery
University of Texas Health Science Center at Houston

ORDER THE STRATICYTE TEST ON-LINE!

Visit proteocyte.com or call: **1-833-5-PROTEO**
(1-833-577-6836)

Email clientservices@proteocyte.com
and we will assist you.

Stay informed of future developments, relevant information, and complimentary webinars.



Scan this QR code or visit caretoknowpro.com to enroll with “Care to know”, North America's leading source of webinars, industry information and peer insights.

The **STRATICYTE** test is a proprietary prognostic test offered by **Proteocyte AI**.

Proteocyte AI is a privately held corporation located in the MaRS Centre on Hospital Row in Toronto Canada.

STRATICYTE™
Predict Oral Cancer Risk

Proteocyte AI
MaRS Centre South Tower
101 College St. Suite 200
Toronto, Canada
M5G 1L7